The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure

被引:135
|
作者
Marber, Michael S. [1 ]
Rose, Beth [2 ,3 ,4 ]
Wang, Yibin [2 ,3 ,4 ]
机构
[1] St Thomas Hosp, Rayne Inst, Div Cardiovasc, Kings Coll London,BHF Ctr,Rayne Inst, London SE1 7EH, England
[2] Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
关键词
p38 kinase mitogen-activated protein kinase; Heart failure; Inhibitor; Therapy; P38-ALPHA MAP KINASE; SIGNAL-TRANSDUCTION; CONTRACTILE DYSFUNCTION; INDEPENDENT ACTIVATION; MYOCARDIAL-INFARCTION; SUSTAINED ISCHEMIA; TYROSINE KINASE; MOUSE MODEL; IN-VITRO; INHIBITION;
D O I
10.1016/j.yjmcc.2010.10.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The p38 mitogen-activated protein kinases (p38s) are stress-activated Ser/Thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1-mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury, and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure." (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:485 / 490
页数:6
相关论文
共 50 条
  • [1] The case for inhibiting p38 mitogen-activated protein kinase in heart failure
    Arabacilar, Pelin
    Marber, Michael
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [2] p38 mitogen-activated protein kinase - A future for heart failure therapy?
    Kerkela, Risto
    Force, Thomas
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) : 556 - 558
  • [3] Dehydroeplandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase
    Ashida, K
    Goto, K
    Zhao, Y
    Okabe, T
    Yanase, T
    Takayanagi, R
    Nomura, M
    Nawata, H
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2005, 1728 (1-2): : 84 - 94
  • [4] p38 mitogen-activated protein kinase and pain
    Mai, Lijia
    Zhu, Xiao
    Huang, Fang
    He, Hongwen
    Fan, Wenguo
    LIFE SCIENCES, 2020, 256
  • [5] p38α Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma
    Yang, Ling
    Sun, Xiaoting
    Ye, Ying
    Lu, Yongtian
    Zuo, Ji
    Liu, Wen
    Elcock, Adrian
    Zhu, Shun
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [6] Mitogen-Activated Protein Kinase p38 Pathway in Venous Ulcer Fibroblasts
    Raffetto, Joseph D.
    Gram, Christopher H.
    Overman, Kristen C.
    Menzoian, James O.
    VASCULAR AND ENDOVASCULAR SURGERY, 2008, 42 (04) : 367 - 374
  • [7] The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis
    Schett, G.
    Zwerina, J.
    Firestein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 909 - 916
  • [8] Role of p38 mitogen-activated protein kinase pathway on heart failure in the infant rat after burn injury
    Kita, Toshiro
    Ogawa, Midori
    Sato, Hiroaki
    Kasai, Kentaro
    Tanaka, Toshiko
    Tanaka, Noriyuki
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2008, 89 (01) : 55 - 63
  • [9] The p38 mitogen-activated protein kinase pathway in interferon signal transduction
    Katsoulidis, E
    Li, YZ
    Mears, H
    Platanias, LC
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2005, 25 (12): : 749 - 756
  • [10] p38 mitogen-activated protein kinase is activated by high glucose
    Tsiani, E
    Fantus, IG
    Whiteside, CI
    DIABETES, 1999, 48 : A68 - A68